Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Gardner TJ, Tortorella D.

Microbiol Mol Biol Rev. 2016 Jun 15;80(3):663-77. doi: 10.1128/MMBR.00018-16. Print 2016 Sep. Review.

2.

Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.

Cui X, Freed DC, Wang D, Qiu P, Li F, Fu TM, Kauvar LM, McVoy MA.

J Virol. 2017 Jun 9;91(13). pii: e01650-16. doi: 10.1128/JVI.01650-16. Print 2017 Jul 1.

3.
4.

Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein.

Gardner TJ, Stein KR, Duty JA, Schwarz TM, Noriega VM, Kraus T, Moran TM, Tortorella D.

Nat Commun. 2016 Dec 14;7:13627. doi: 10.1038/ncomms13627.

5.

Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies.

Kropff B, Burkhardt C, Schott J, Nentwich J, Fisch T, Britt W, Mach M.

PLoS Pathog. 2012;8(10):e1002999. doi: 10.1371/journal.ppat.1002999. Epub 2012 Oct 25.

6.

CMV immune evasion and manipulation of the immune system with aging.

Jackson SE, Redeker A, Arens R, van Baarle D, van den Berg SPH, Benedict CA, Čičin-Šain L, Hill AB, Wills MR.

Geroscience. 2017 Jun;39(3):273-291. doi: 10.1007/s11357-017-9986-6. Epub 2017 Jun 24.

7.

A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?

Ohlin M.

Mol Immunol. 2014 Aug;60(2):95-102. doi: 10.1016/j.molimm.2014.03.015. Epub 2014 May 4.

PMID:
24802891
8.

Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes.

Loughney JW, Rustandi RR, Wang D, Troutman MC, Dick LW Jr, Li G, Liu Z, Li F, Freed DC, Price CE, Hoang VM, Culp TD, DePhillips PA, Fu TM, Ha S.

J Biol Chem. 2015 Jun 26;290(26):15985-95. doi: 10.1074/jbc.M115.652230. Epub 2015 May 6.

9.

Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo.

Lilleri D, Kabanova A, Lanzavecchia A, Gerna G.

J Clin Immunol. 2012 Dec;32(6):1324-31. doi: 10.1007/s10875-012-9739-3. Epub 2012 Jul 27.

PMID:
22836657
10.

Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets.

McCutcheon KM, Gray J, Chen NY, Liu K, Park M, Ellsworth S, Tripp RA, Tompkins SM, Johnson SK, Samet S, Pereira L, Kauvar LM.

MAbs. 2014 Mar-Apr;6(2):460-73. doi: 10.4161/mabs.27760. Epub 2014 Jan 8.

11.

Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Cui X, Adler SP, Schleiss MR, Arav-Boger R, Demmler Harrison GJ, McVoy MA.

Clin Vaccine Immunol. 2017 Jun 5;24(6). pii: e00024-17. doi: 10.1128/CVI.00024-17. Print 2017 Jun.

12.
13.

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.

Cui X, Meza BP, Adler SP, McVoy MA.

Vaccine. 2008 Oct 23;26(45):5760-6. doi: 10.1016/j.vaccine.2008.07.092. Epub 2008 Aug 19.

14.

Diverse immune evasion strategies by human cytomegalovirus.

Noriega V, Redmann V, Gardner T, Tortorella D.

Immunol Res. 2012 Dec;54(1-3):140-51. doi: 10.1007/s12026-012-8304-8. Review.

PMID:
22454101
15.

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity.

Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ.

N Engl J Med. 2001 May 3;344(18):1366-71.

16.

Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.

Navarro D, Lennette E, Tugizov S, Pereira L.

J Med Virol. 1997 Aug;52(4):451-9.

PMID:
9260696
17.

Cytomegalovirus and HIV Persistence: Pouring Gas on the Fire.

Christensen-Quick A, Vanpouille C, Lisco A, Gianella S.

AIDS Res Hum Retroviruses. 2017 Nov;33(S1):S23-S30. doi: 10.1089/aid.2017.0145. Review.

18.

Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors.

Ishibashi K, Tokumoto T, Shirakawa H, Hashimoto K, Ikuta K, Kushida N, Yanagida T, Shishido K, Aikawa K, Toma H, Inoue N, Yamaguchi O, Tanabe K, Suzutani T.

Transpl Infect Dis. 2011 Jun;13(3):318-23. doi: 10.1111/j.1399-3062.2010.00563.x. Epub 2010 Aug 30.

PMID:
20804536
19.

Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions.

Manley K, Anderson J, Yang F, Szustakowski J, Oakeley EJ, Compton T, Feire AL.

Cell Host Microbe. 2011 Sep 15;10(3):197-209. doi: 10.1016/j.chom.2011.07.010.

20.

Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Gardner TJ, Bolovan-Fritts C, Teng MW, Redmann V, Kraus TA, Sperling R, Moran T, Britt W, Weinberger LS, Tortorella D.

Clin Vaccine Immunol. 2013 Apr;20(4):540-50. doi: 10.1128/CVI.00644-12. Epub 2013 Feb 6.

Supplemental Content

Support Center